Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 3/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | BRAF | P15056 | 1/20 | 0.49 |
| ▸ | EIF2AK3 | Q9NZJ5 | 1/20 | 0.49 |
| ▸ | NR1I3 | Q14994 | 4/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2000609 | 0.92 | BAZ2B (0.67) | BAZ2BRAB9ANPC1CYP1A2CYP3A4 | |
| SCHEMBL6193791 | 0.92 | BAZ2B (0.63) | BAZ2BRAB9ANPC1CYP1A2CYP3A4 | |
| SCHEMBL1091597 | 0.85 | BAZ2B (0.60) | BAZ2BRAB9ANPC1KMT2AMEN1 | |
| SCHEMBL6240743 | 0.85 | RAB9A (0.46) | BAZ2BRAB9ANPC1CYP1A2CYP3A4 | |
| SCHEMBL6238287 | 0.85 | NPC1 (0.46) | BAZ2BRAB9ANPC1CYP1A2CYP3A4 | |
| SCHEMBL4916631 | 0.82 | MAPT (0.58) | RAB9ANPC1KMT2ALMNAMEN1 | |
| SCHEMBL20809837 | 0.82 | TP53 (0.56) | RAB9ANPC1TSHRALDH1A1SMN1; SMN2 | |
| SCHEMBL20809725 | 0.81 | BAZ2B (0.55) | BAZ2BRAB9ANPC1NR1I3 | |
| SCHEMBL30781540 | 0.81 | BAZ2B (0.55) | BAZ2BRAB9ANPC1NR1I3 | |
| SCHEMBL15190881 | 0.81 | BAZ2B (0.60) | BAZ2BRAB9ANPC1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8338487-B2 | Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and -2,3-dihydro-1H-indenes as potassium channel modulators | VALEANT PHARMACEUTICALS INTERNATIONAL, INC. (US) | 2012-12-25 | — | — | US | disclosed |
| US-8338487-B2 | Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and -2,3-dihydro-1H-indenes as potassium channel modulators | VALEANT PHARMACEUTICALS INTERNATIONAL, INC. (US) | 2012-12-25 | — | — | US | disclosed |
| EP-2086925-B1 | 1,4 DIAMINO BICYCLIC RETIGABINE ANALOGUES AS POTASSIUM CHANNEL MODULATORS | VALEANT PHARMACEUTICALS INT (US) | 2011-12-21 | — | — | EP | disclosed |
| EP-2086925-B1 | 1,4 DIAMINO BICYCLIC RETIGABINE ANALOGUES AS POTASSIUM CHANNEL MODULATORS | VALEANT PHARMACEUTICALS INT (US) | 2011-12-21 | — | — | EP | disclosed |
| US-8030518-B2 | E.g., N-(5-(4-fluorophenylamino)-1,3-dimethyl-5,6,7,8-tetrahydronaphthalen-2-yl)-3,3-dimethylbutanamide; treating or preventing neuropathic and chronic pain, bipolar disorder, migraine, epilepsy, a seizure or a disorder characterized by a seizure | VALEANT PHARMACEUTICALS INTERNATIONAL (US) | 2011-10-04 | — | — | US | disclosed |
| US-8030518-B2 | E.g., N-(5-(4-fluorophenylamino)-1,3-dimethyl-5,6,7,8-tetrahydronaphthalen-2-yl)-3,3-dimethylbutanamide; treating or preventing neuropathic and chronic pain, bipolar disorder, migraine, epilepsy, a seizure or a disorder characterized by a seizure | VALEANT PHARMACEUTICALS INTERNATIONAL (US) | 2011-10-04 | — | — | US | disclosed |
| US-8030518-B2 | E.g., N-(5-(4-fluorophenylamino)-1,3-dimethyl-5,6,7,8-tetrahydronaphthalen-2-yl)-3,3-dimethylbutanamide; treating or preventing neuropathic and chronic pain, bipolar disorder, migraine, epilepsy, a seizure or a disorder characterized by a seizure | VALEANT PHARMACEUTICALS INTERNATIONAL (US) | 2011-10-04 | — | — | US | disclosed |
| US-20110207812-A1 | SUBSTITUTED ARYLAMINO-1,2,3,4-TETRAHYDRO NAPHTHALENES AND -2,3-DIHYDRO-1H-INDENES AS POTASSIUM CHANNEL MODULATORS | ORAPHARMA, INC. | 2011-08-25 | — | — | US | disclosed |
| US-20110207812-A1 | SUBSTITUTED ARYLAMINO-1,2,3,4-TETRAHYDRO NAPHTHALENES AND -2,3-DIHYDRO-1H-INDENES AS POTASSIUM CHANNEL MODULATORS | ORAPHARMA, INC. | 2011-08-25 | — | — | US | disclosed |
| US-7960436-B2 | Therapy and prophylaxis of diseases and disorders such as seizure disorders; [1-Amino-5-(4-trifluoromethyl-phenylamino)-5,6,7,8-tetrahydro-naphthalen-2-yl]-carbamic acid ethyl ester | VALEANT PHARMACEUTICALS INTERNATIONAL (US) | 2011-06-14 | — | — | US | disclosed |
| US-20080234334-A1 | 1,4 DIAMINO BICYCLIC RETIGABINE ANALOGUES AS POTASSIUM CHANNEL MODULATORS | VALEANT PHARMACEUTICALS INTERNATIONAL (US) | 2008-09-25 | — | — | US | disclosed |
| US-20080234334-A1 | 1,4 DIAMINO BICYCLIC RETIGABINE ANALOGUES AS POTASSIUM CHANNEL MODULATORS | VALEANT PHARMACEUTICALS INTERNATIONAL (US) | 2008-09-25 | — | — | US | disclosed |
| US-20080234334-A1 | 1,4 DIAMINO BICYCLIC RETIGABINE ANALOGUES AS POTASSIUM CHANNEL MODULATORS | VALEANT PHARMACEUTICALS INTERNATIONAL (US) | 2008-09-25 | — | — | US | disclosed |
| US-20080146661-A1 | Substituted arylamino -1,2,3,4-tetrahydro naphthalenes and -2,3-dihydro-1H-indenes as potassium channel modulators | VALEANT PHARMACEUTICALS NORTH AMERICA (US) | 2008-06-19 | — | — | US | disclosed |
| US-20080146661-A1 | Substituted arylamino -1,2,3,4-tetrahydro naphthalenes and -2,3-dihydro-1H-indenes as potassium channel modulators | VALEANT PHARMACEUTICALS NORTH AMERICA (US) | 2008-06-19 | — | — | US | disclosed |
| US-20080146661-A1 | Substituted arylamino -1,2,3,4-tetrahydro naphthalenes and -2,3-dihydro-1H-indenes as potassium channel modulators | VALEANT PHARMACEUTICALS NORTH AMERICA (US) | 2008-06-19 | — | — | US | disclosed |
| WO-2008066900-A1 | 1,4 DIAMINO BICYCLIC RETIGABINE ANALOGUES AS POTASSIUM CHANNEL MODULATORS | VALEANT PHARMACEUTICALS INTERNATIONAL (US) | 2008-06-05 | — | — | WO | disclosed |
| WO-2008066900-A1 | 1,4 DIAMINO BICYCLIC RETIGABINE ANALOGUES AS POTASSIUM CHANNEL MODULATORS | VALEANT PHARMACEUTICALS INTERNATIONAL (US) | 2008-06-05 | — | — | WO | disclosed |
| US-4616013-A | INOTROPIC AND VASODILATOR ACTIVITY | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1986-10-07 | — | — | US | disclosed |
| EP-0145236-A2 | Thiadiazinone compounds, process for their preparation, and pharmaceutical compositions containing them | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1985-06-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207812-A1 | SUBSTITUTED ARYLAMINO-1,2,3,4-TETRAHYDRO NAPHTHALENES AND -2,3-DIHYDRO-1H-INDENES AS POTASSIUM CHANNEL MODULATORS | SCN1B, SCN1A, SCN4A | BAZ2B 1954/4885RAB9A 1815/4885NPC1 329/4885 |
| US-20080234334-A1 | 1,4 DIAMINO BICYCLIC RETIGABINE ANALOGUES AS POTASSIUM CHANNEL MODULATORS | KCNB2, KCNB1, KCNA1 | BAZ2B 3743/4885RAB9A 849/4885NPC1 720/4885 |
| US-20080146661-A1 | Substituted arylamino -1,2,3,4-tetrahydro naphthalenes and -2,3-dihydro-1H-indenes as potassium channel modulators | SCN1B, SCN1A, SCN4A | BAZ2B 1807/4885RAB9A 1730/4885NPC1 326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.